299 related articles for article (PubMed ID: 30449217)
21. Patterns of Care Among Real-World Patients with Metastatic Neuroendocrine Tumors.
Klink AJ; Feinberg B; Yu HT; Ray D; Pulgar S; Phan A; Vinik A
Oncologist; 2019 Oct; 24(10):1331-1339. PubMed ID: 31015313
[TBL] [Abstract][Full Text] [Related]
22. Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis.
Rustgi SD; Oh A; Yang JY; Kang D; Wolin E; Kong CY; Hur C; Kim MK
BMC Cancer; 2021 May; 21(1):597. PubMed ID: 34030646
[TBL] [Abstract][Full Text] [Related]
23. Echocardiography in functional midgut neuroendocrine tumors: When and how often.
Castillo JG; Naib T; Zacks JS; Adams DH
Rev Endocr Metab Disord; 2017 Dec; 18(4):411-421. PubMed ID: 29080935
[TBL] [Abstract][Full Text] [Related]
24. Clinical characteristics, treatment patterns, and economic burden in patients treated for neuroendocrine tumors in the United States: a retrospective cohort study.
Chuang CC; Bhurke S; Chen SY; Brulais S; Gabriel S
J Med Econ; 2015 Feb; 18(2):126-36. PubMed ID: 25325180
[TBL] [Abstract][Full Text] [Related]
25. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
Saif MW
Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
[TBL] [Abstract][Full Text] [Related]
26. Chromogranin A (CgA) as a biomarker in carcinoid heart disease and NETG1/G2 neuroendocrine neoplasms of the small intestine (SI-NENs) related carcinoid syndrome.
Konsek-Komorowska SJ; Pęczkowska M; Kolasińska-Ćwikła AD; Konka M; Chrapowicki E; Ćwikła JB
Med Clin (Barc); 2022 Jul; 159(2):85-89. PubMed ID: 34736622
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs.
Joish VN; Frech F; Lapuerta P
J Med Econ; 2018 Feb; 21(2):182-188. PubMed ID: 28959913
[TBL] [Abstract][Full Text] [Related]
28. Carcinoid Heart Disease Management: A Multi-Disciplinary Collaboration.
Das S; Stockton SS; Hassan SA
Oncologist; 2023 Jul; 28(7):575-583. PubMed ID: 37209415
[TBL] [Abstract][Full Text] [Related]
29. Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences.
Ryan P; Phan AT; Adelman DT; Iwasaki M
Clin J Oncol Nurs; 2016 Dec; 20(6):E139-E146. PubMed ID: 27857269
[TBL] [Abstract][Full Text] [Related]
30. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
[TBL] [Abstract][Full Text] [Related]
31. [Carcinoid heart disease].
Bencze A; Szücs N; Igaz P; Leiszter K; Nagy Z; Patócs A; Rácz K
Orv Hetil; 2013 Apr; 154(14):546-50. PubMed ID: 23545233
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathologic characteristics of 127 cases of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) studied in an oncology hospital].
Alvarado-Cabrero I; de Anda-González J; Hernández-Hernández B; Mantilla-Morales A; Valencia-Cedillo R; Medrano-Guzmán R
Rev Gastroenterol Mex; 2012; 77(4):174-80. PubMed ID: 23142406
[TBL] [Abstract][Full Text] [Related]
33. Breakthrough Symptoms Remain an Unmet Need in Symptomatic Patients With Neuroendocrine Tumors and Carcinoid Syndrome.
Liu E; Hoffman KD; Murfin G; Eccard H
Pancreas; 2023 Jan; 52(1):e70-e74. PubMed ID: 37378902
[TBL] [Abstract][Full Text] [Related]
34. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective.
Joish VN; Frech F; Lapuerta P
Clin Ther; 2017 Dec; 39(12):2338-2344. PubMed ID: 29175096
[TBL] [Abstract][Full Text] [Related]
35. Carcinoid Heart Disease: a Review.
Laskaratos FM; Davar J; Toumpanakis C
Curr Oncol Rep; 2021 Mar; 23(4):48. PubMed ID: 33725214
[TBL] [Abstract][Full Text] [Related]
36. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome.
Fust K; Maschio M; Kohli M; Singh S; Pritchard DM; Marteau F; Myrenfors P; Feuilly M
Pharmacoeconomics; 2020 Jun; 38(6):607-618. PubMed ID: 32157590
[TBL] [Abstract][Full Text] [Related]
37. Carcinoid syndrome: update on the pathophysiology and treatment.
Rubin de Celis Ferrari AC; Glasberg J; Riechelmann RP
Clinics (Sao Paulo); 2018 Aug; 73(suppl 1):e490s. PubMed ID: 30133565
[TBL] [Abstract][Full Text] [Related]
38. Health-related quality of life in well-differentiated metastatic gastroenteropancreatic neuroendocrine tumors.
Jiménez-Fonseca P; Carmona-Bayonas A; Martín-Pérez E; Crespo G; Serrano R; Llanos M; Villabona C; García-Carbonero R; Aller J; Capdevila J; Grande E;
Cancer Metastasis Rev; 2015 Sep; 34(3):381-400. PubMed ID: 26245646
[TBL] [Abstract][Full Text] [Related]
39. Economic analysis of inadequate symptom control in carcinoid syndrome in the United States.
Burton T; Lapuerta P
Future Oncol; 2018 Oct; 14(23):2361-2370. PubMed ID: 30095284
[TBL] [Abstract][Full Text] [Related]
40. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important.
Jin XF; Spampatti MP; Spitzweg C; Auernhammer CJ
Rev Endocr Metab Disord; 2018 Jun; 19(2):145-158. PubMed ID: 29464446
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
